VolitionRx Ltd (VNRX) stock
Close on Nov 11, 2026Market cap $2.78MP/E –Yield –
VolitionRx Ltd grew revenue 86.3% to $2.46M over the twelve months to Jun 30, 2026. Free cash flow was -$19.58M. At the latest close the market valued the company at $2.78M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $2.78M
- P/E ratio
- –
- Price to sales
- 1.13
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -704.72%
Fundamentals
- Revenue
- $2.46M
- Net income
- -$25.64M
- EPS, diluted
- -$3.86
- Free cash flow
- -$19.58M
- Book value per share
- -$3.51
- Diluted shares
- 9M
Trading
- Next earnings
- Nov 12, 2026 (estimated, during market hours)
- Previous close
- $0.18
- Open
- $0.19
- Day's range
- $0.19 – $0.20
- Volume
- 681,852
- Average volume (20 days)
- 987,814
- Beta (5 years)
- 0.98
- 52-week range
- $0.16 – $8.13
- RSI (14 days)
- 47.1
- Volatility (1 year)
- 107.2%
- Relative volume
- 0.11×
- WACC
- 6.7%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | VNRX | S&P 500 | Difference | VNRX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -3.6% | -2.4% | −1.2 pts | ||
| 3 months | -71.5% | -1.2% | −70.4 pts | ||
| Year to date | -96.0% | +12.3% | −108.3 pts | ||
| 1 year | -97.3% | +12.4% | −109.8 pts | ||
| 3 years | -98.8% | +78.8% | −177.7 pts | -77.4% | +21.4% |
| 5 years | -99.7% | +75.2% | −174.9 pts | -69.2% | +11.9% |
| 10 years | -99.8% | +311.1% | −410.9 pts | -45.4% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases VolitionRx filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- News
- Results
- News
About VolitionRx
In Vitro & In Vivo Diagnostic Substances
VolitionRx Limited is a multi-national epigenetics company that develops blood-based tests to detect and monitor cancer and diseases associated with NETosis, such as sepsis. Its patented technologies, including Nu.Q and Capture-PCR/Capture-Seq, analyze circulating nucleosomes, transcription factors, and tumor-derived DNA in the blood to identify disease changes at early stages. The company's key product pillars encompass Nu.Q Vet for canine cancer screening and companion animal diagnostics, Nu.Q NETs for conditions linked to NETosis, Nu.Q Discover for nucleosome profiling in drug research, and Nu.Q Cancer for human oncology detection and monitoring. Volition serves veterinarians, pet owners, academic institutions, diagnostic providers, and pharmaceutical researchers.
Company profile, executives and historyVolitionRx stock: common questions
What is VolitionRx's stock price?
VNRX closed at $0.20 on Nov 11, 2026, up 10.41% on the day. Over the past 52 weeks it traded between $0.16 and $8.13.
What is VolitionRx's market cap?
VolitionRx was worth $2.78M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is VNRX's P/E ratio?
VolitionRx lost money over the twelve months to Jun 30, 2026 (diluted EPS -$3.86), so it has no meaningful P/E ratio.
How much revenue does VolitionRx make?
VolitionRx reported revenue of $2.46M for the twelve months to Jun 30, 2026, up 86.3% from a year earlier.
Does VolitionRx pay a dividend?
No. VolitionRx has not paid a cash dividend over the last twelve months.
When does VolitionRx report earnings next?
VolitionRx is expected to report Q3 FY2026 results on Nov 12, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has VNRX stock performed over the past year?
Including dividends, VNRX returned -97.3% over the past year, against +12.4% for the S&P 500.
Who are VolitionRx's competitors?
Companies most similar to VolitionRx by business, industry and size include BMRA, IMDX, NWBO, XBIO, PRPH.
See a number that looks wrong?